

# company announcement

## Novo Nordisk A/S – Share repurchase programme

**Bagsværd, Denmark, 20 April 2026** – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.

Since the announcement 13 April 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
<b>Accumulated, last announcement</b>	<b>11,007,992</b>		<b>2,835,176,799</b>
13 April 2026	260,000	237.12	61,650,199
14 April 2026	260,000	246.63	64,124,056
15 April 2026	250,000	253.43	63,358,536
16 April 2026	240,000	259.91	62,378,913
17 April 2026	240,000	258.43	62,022,304
<b>Accumulated under the programme</b>	<b>12,257,992</b>		<b>3,148,710,807</b>

The details for each transaction made under the share repurchase programme are published on [novonordisk.com](https://novonordisk.com).

With the transactions stated above, Novo Nordisk owns a total of 29,647,791 B shares of DKK 0.10 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 17 April 2026, Novo Nordisk has since 4 February 2026 repurchased a total 12,257,992 B shares at an average share price of DKK 256.87 per B share equal to a transaction value of DKK 3,148,710,807.

*Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).*

## Contacts for further information

### Media:

**Ambre James-Brown**

+45 3079 9289

[globalmedia@novonordisk.com](mailto:globalmedia@novonordisk.com)

**Liz Skrbkova (US)**

+1 609 917 0632

[lzsk@novonordisk.com](mailto:lzsk@novonordisk.com)

### Investors:

**Michael Novod**

+45 3075 6050

[nvno@novonordisk.com](mailto:nvno@novonordisk.com)

**Max Ung**

+45 3077 6414

[mxun@novonordisk.com](mailto:mxun@novonordisk.com)

**Alex Bruce**

+45 34 44 26 13

[axeu@novonordisk.com](mailto:axeu@novonordisk.com)

**Frederik Taylor Pitter**

+1 609 613 0568

[fpitr@novonordisk.com](mailto:fpitr@novonordisk.com)

**Jacob Martin Wiborg Rode**

+45 3075 5956

[jrde@novonordisk.com](mailto:jrde@novonordisk.com)

**Sina Meyer**

+45 3079 6656

[azey@novonordisk.com](mailto:azey@novonordisk.com)

**Christoffer Sho Togo Tullin**

+45 3079 1471

[cftu@novonordisk.com](mailto:cftu@novonordisk.com)